야간 빈뇨 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2031년) - 적응증별, 약물 유형별, 유통 채널별, 지역별

Nocturia Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

US $ 4,995 ￦ 6,879,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,699,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,598,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이 보고서는 세계 야간 빈뇨 시장에 대해 조사했으며, 시장 개요와 함께 적응증별/약품 유형별/유통 채널별/지역별 동향, 시장 진출기업의 경쟁 동향 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter의 Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나·러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 야간 빈뇨 시장 전망, 2018년-2031년

• 세계의 야간 빈뇨 시장 전망, 적응증별, 금액(10억 달러), 2018년-2031년
• 세계의 야간 빈뇨 시장 전망, 약제 유형별, 금액(10억 달러), 2018년-2031년
• 세계의 야간 빈뇨 시장 전망, 유통 채널별, 금액(10억 달러), 2018년-2031년
• 세계의 야간 빈뇨 시장 전망, 지역별, 금액(10억 달러), 2018년-2031년

제4장 북미의 야간 빈뇨 시장 전망, 2018년-2031년

제5장 유럽의 야간 빈뇨 시장 전망, 2018년-2031년

제6장 아시아태평양의 야간 빈뇨 시장 전망, 2018년-2031년

제7장 라틴아메리카의 야간 빈뇨 시장 전망, 2018년-2031년

제8장 중동 및 아프리카의 야간 빈뇨 시장 전망, 2018년-2031년

제9장 경쟁 구도

• 적응증 vs. 유통 채널 히트맵
• 제조업체와 유통 채널 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁 대시보드
• 기업 개요
  • Allergan, Inc.
  • Urigen Pharmaceuticals
  • Ferring Pharmaceuticals
  • Glenmark Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AA Pharma Inc.
  • Avadel Pharmaceuticals plc

제10장 부록

LSH

영문 목차

영문목차

Fairfield Market Research a leading provider of market research reports, has released a comprehensive analysis of the global nocturia market spanning the period 2024-2031. The report aims to provide industry stakeholders with valuable updates on market trends and opportunities within the global landscape.

Rising Disease Prevalence Fuels Market Growth

The primary objective of the report is to shed light on developments in the Nocturia market that are reshaping businesses worldwide. Factors such as the increasing prevalence of cancer, diabetes, and cardiovascular diseases on a global scale have significantly contributed to the market's revenue growth. With a substantial portion of the population affected by these ailments, there is a growing demand for treatments targeting nocturia symptoms.

Driving Forces and Market Opportunities

The report highlights the factors expected to drive revenue growth in the global nocturia market, including greater access to manufacturing infrastructure, increased utilization of Contract Manufacturing Organizations (CMOs), and advancements in drug delivery systems. However, it also acknowledges challenges such as high operational costs and competition from low-cost manufacturers, which could potentially hinder market expansion.

Market Segmentation and Forecast

Fairfield Market Research analysis explores the global nocturia market performance, categorizing revenue contributions by different drug types. Among them, Desmopressin is anticipated to maintain its market leadership, with a projected growth rate throughout the forecast period. The Desmopressin segment's valuation, recorded in the past, is expected to see significant growth by the end of the assessment period.

Competitive Analysis

In the competitive assessment section, the report provides a detailed analysis of key market players, offering insights into their long-term and short-term strategies. Major manufacturing companies such as Allergan, Inc., Urigen Pharmaceuticals, Ferring Pharmaceuticals, Glenmark Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AA Pharma Inc., and Avadel Pharmaceuticals plc are profiled, highlighting their product offerings and recent developments in the nocturia market.

Emphasis on Decision-Making Insights

The report includes impact analyses of key trends, drivers, challenges, and opportunities to equip clients with actionable information for strategic decision-making. Additionally, it features a competitive landscape with a dashboard view, enabling stakeholders to discern key differentiators among competitor firms.

Global Nocturia Market: Segmentation

Market segmentation by indication

• Mixed nocturia
• Low nocturnal bladder capacity
• Nocturnal polyuria
• Global polyuria

Market segmentation by drug type

• Anticholinergic drugs
• Desmopressin
• Antibiotics
• Antispasmodic
• Others

Market segmentation by distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Market Segmentation by region

• North America
• Latin America
• Europe
• Asia Pacific excluding Japan
• Japan
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Nocturia Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Nocturia Market Outlook, 2018 - 2031

• 3.1. Global Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Mixed nocturia
    • 3.1.1.2. Low nocturnal bladder capacity
    • 3.1.1.3. Nocturnal polyuria
    • 3.1.1.4. Global polyuria
• 3.2. Global Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Anticholinergic drugs
    • 3.2.1.2. Desmopressin
    • 3.2.1.3. Antispasmodic
    • 3.2.1.4. Others
• 3.3. Global Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Hospital Pharmacies
    • 3.3.1.2. Retail Pharmacies
    • 3.3.1.3. Drug Stores
    • 3.3.1.4. Online Pharmacies
• 3.4. Global Nocturia Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. North America
    • 3.4.1.2. Europe
    • 3.4.1.3. Asia Pacific
    • 3.4.1.4. Latin America
    • 3.4.1.5. Middle East & Africa

4. North America Nocturia Market Outlook, 2018 - 2031

• 4.1. North America Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Mixed nocturia
    • 4.1.1.2. Low nocturnal bladder capacity
    • 4.1.1.3. Nocturnal polyuria
    • 4.1.1.4. Global polyuria
• 4.2. North America Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Anticholinergic drugs
    • 4.2.1.2. Desmopressin
    • 4.2.1.3. Antispasmodic
    • 4.2.1.4. Others
• 4.3. North America Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Hospital Pharmacies
    • 4.3.1.2. Retail Pharmacies
    • 4.3.1.3. Drug Stores
    • 4.3.1.4. Online Pharmacies
• 4.4. North America Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.4.1. Key Highlights
    • 4.4.1.1. U.S. Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.4.1.2. U.S. Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.4.1.3. U.S. Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.1.4. Canada Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.4.1.5. Canada Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.4.1.6. Canada Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Nocturia Market Outlook, 2018 - 2031

• 5.1. Europe Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Mixed nocturia
    • 5.1.1.2. Low nocturnal bladder capacity
    • 5.1.1.3. Nocturnal polyuria
    • 5.1.1.4. Global polyuria
• 5.2. Europe Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Anticholinergic drugs
    • 5.2.1.2. Desmopressin
    • 5.2.1.3. Antispasmodic
    • 5.2.1.4. Others
• 5.3. Europe Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Hospital Pharmacies
    • 5.3.1.2. Retail Pharmacies
    • 5.3.1.3. Drug Stores
    • 5.3.1.4. Online Pharmacies
• 5.4. Europe Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.4.1. Key Highlights
    • 5.4.1.1. Germany Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.2. Germany Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.3. Germany Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.4. U.K. Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.5. U.K. Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.6. U.K. Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.7. France Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.8. France Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.9. France Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.10. Italy Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.11. Italy Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.12. Italy Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.13. Turkey Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.14. Turkey Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.15. Turkey Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.16. Russia Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.17. Russia Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.18. Russia Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.19. Rest of Europe Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.20. Rest of Europe Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.21. Rest of Europe Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Nocturia Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Mixed nocturia
    • 6.1.1.2. Low nocturnal bladder capacity
    • 6.1.1.3. Nocturnal polyuria
    • 6.1.1.4. Global polyuria
• 6.2. Asia Pacific Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Anticholinergic drugs
    • 6.2.1.2. Desmopressin
    • 6.2.1.3. Antispasmodic
    • 6.2.1.4. Others
• 6.3. Asia Pacific Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. Hospital Pharmacies
    • 6.3.1.2. Retail Pharmacies
    • 6.3.1.3. Drug Stores
    • 6.3.1.4. Online Pharmacies
• 6.4. Asia Pacific Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.4.1. Key Highlights
    • 6.4.1.1. China Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.2. China Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.3. China Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.4. Japan Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.5. Japan Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.6. Japan Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.7. South Korea Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.8. South Korea Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.9. South Korea Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.10. India Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.11. India Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.12. India Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.13. Southeast Asia Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.14. Southeast Asia Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.15. Southeast Asia Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.16. Rest of Asia Pacific Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.17. Rest of Asia Pacific Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.18. Rest of Asia Pacific Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Nocturia Market Outlook, 2018 - 2031

• 7.1. Latin America Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Mixed nocturia
    • 7.1.1.2. Low nocturnal bladder capacity
    • 7.1.1.3. Nocturnal polyuria
    • 7.1.1.4. Global polyuria
• 7.2. Latin America Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Anticholinergic drugs
    • 7.2.1.2. Desmopressin
    • 7.2.1.3. Antispasmodic
    • 7.2.1.4. Others
• 7.3. Latin America Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Hospital Pharmacies
    • 7.3.1.2. Retail Pharmacies
    • 7.3.1.3. Drug Stores
    • 7.3.1.4. Online Pharmacies
• 7.4. Latin America Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.4.1. Key Highlights
    • 7.4.1.1. Brazil Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.4.1.2. Brazil Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.4.1.3. Brazil Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1.4. Mexico Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.4.1.5. Mexico Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.4.1.6. Mexico Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1.7. Argentina Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.4.1.8. Argentina Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.4.1.9. Argentina Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1.10. Rest of Latin America Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.4.1.11. Rest of Latin America Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.4.1.12. Rest of Latin America Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Nocturia Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Nocturia Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Mixed nocturia
    • 8.1.1.2. Low nocturnal bladder capacity
    • 8.1.1.3. Nocturnal polyuria
    • 8.1.1.4. Global polyuria
• 8.2. Middle East & Africa Nocturia Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Anticholinergic drugs
    • 8.2.1.2. Desmopressin
    • 8.2.1.3. Antispasmodic
    • 8.2.1.4. Others
• 8.3. Middle East & Africa Nocturia Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. Hospital Pharmacies
    • 8.3.1.2. Retail Pharmacies
    • 8.3.1.3. Drug Stores
    • 8.3.1.4. Online Pharmacies
• 8.4. Middle East & Africa Nocturia Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.4.1. Key Highlights
    • 8.4.1.1. GCC Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.2. GCC Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.3. GCC Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1.4. South Africa Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.5. South Africa Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.6. South Africa Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1.7. Egypt Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.8. Egypt Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.9. Egypt Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1.10. Nigeria Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.11. Nigeria Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.12. Nigeria Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1.13. Rest of Middle East & Africa Nocturia Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.14. Rest of Middle East & Africa Nocturia Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.15. Rest of Middle East & Africa Nocturia Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Indication vs Distribution Channel Heatmap
• 9.2. Manufacturer vs Distribution Channel Heatmap
• 9.3. Company Market Share Analysis, 2023
• 9.4. Competitive Dashboard
• 9.5. Company Profiles
  • 9.5.1. Allergan, Inc.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Indication Portfolio
    • 9.5.1.3. Financial Overview
    • 9.5.1.4. Business Strategies and Development
  • 9.5.2. Urigen Pharmaceuticals
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Indication Portfolio
    • 9.5.2.3. Financial Overview
    • 9.5.2.4. Business Strategies and Development
  • 9.5.3. Ferring Pharmaceuticals
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Indication Portfolio
    • 9.5.3.3. Financial Overview
    • 9.5.3.4. Business Strategies and Development
  • 9.5.4. Glenmark Pharmaceuticals Inc.
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Indication Portfolio
    • 9.5.4.3. Financial Overview
    • 9.5.4.4. Business Strategies and Development
  • 9.5.5. Teva Pharmaceutical Industries Ltd.
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Indication Portfolio
    • 9.5.5.3. Financial Overview
    • 9.5.5.4. Business Strategies and Development
  • 9.5.6. AA Pharma Inc.
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Indication Portfolio
    • 9.5.6.3. Financial Overview
    • 9.5.6.4. Business Strategies and Development
  • 9.5.7. Avadel Pharmaceuticals plc
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Indication Portfolio
    • 9.5.7.3. Financial Overview
    • 9.5.7.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료